Physician profile
Daniel J Aronson
NPI 1871602755
$1,064.66
in general payments reported to CMS, 2019-2025
15 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $107 · 2021: $193 · 2022: $45.25 · 2023: $173 · 2024: $35.42 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.41 | 2020-2025 | Lo Loestrin Fe |
| Duchesnay USA Incorporated | $164.92 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $101.02 | 2019 | |
| Shield Therapeutics INC | $89.52 | 2023-2024 | Accrufer |
| Vertical Pharmaceuticals, LLC | $71.63 | 2019-2020 | |
| Sage Therapeutics, LLC | $63.16 | 2025 | Zurzuvae |
| Organon LLC | $49.37 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $47.94 | 2019-2020 | |
| Coopersurgical, INC. | $44.39 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Lupin INC. | $32.05 | 2019 | |
| Mission Pharmacal Company | $16.91 | 2020 | |
| Hologic Sales and Service, LLC | $15.12 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.35 | 2025 | Qelbree |
| Merck Sharp & Dohme LLC | $12.50 | 2021 | |
| Avion Pharmaceuticals | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Aronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.